Prosecution Insights
Last updated: August 06, 2026

Millennium Pharmaceuticals Inc.

7 pending office actions • 5 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
4
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (14%)
4
Medium (57%)
1
Easy (14%)
1
Unknown (14%)

Rejection Statute Mix

BucketCases
§103 only1 (14%)
§112 only1 (14%)
Double-patenting + other3 (43%)
Multi-statute (no §101)1 (14%)
No statute on record1 (14%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HADDAD, MAHER M 2 50.5% +53.9%
WHITE, DAWANNA SHAR-DAY 1 62.8% +19.6%
PARK, HAEJIN S 1 55.1% +38.5%
PACKARD, BENJAMIN J 1 66.5% +15.6%
KIM, YUNSOO 1 65.8% +34.8%
ALDARONDO, DASIA ALI 1 0.0% +0.0%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17655541 METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS HADDAD, MAHER M 67d overdue
16084383 METHOD OF PREVENTING GRAFT VERSUS HOST DISEASE ALDARONDO, DASIA ALI

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18731923 ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS WHITE, DAWANNA SHAR-DAY 98d overdue
17655541 METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS HADDAD, MAHER M 67d overdue
17919952 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF PACKARD, BENJAMIN J 28d overdue
18462342 SOLID PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION PARK, HAEJIN S
17652090 FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY KIM, YUNSOO
16084392 METHODS OF TREATING OR PREVENTING GRAFT VERSUS HOST DISEASE HADDAD, MAHER M

Top Art Units

Art UnitApps
1641 3
1627 1
1614 1
1612 1
1600 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18731923 ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS WHITE, DAWANNA SHAR-DAY 1627 §103DP Final Rejection 98d overdue Pending Jun 03, 2024
18462342 SOLID PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION PARK, HAEJIN S 1614 §102§112DP Non-Final OA Pending Sep 06, 2023
17919952 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF PACKARD, BENJAMIN J 1612 Final Rejection 28d overdue Pending Oct 19, 2022
17655541 METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS HADDAD, MAHER M 1641 §102§103 Non-Final OA 67d overdue Pending Mar 18, 2022
17652090 FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY KIM, YUNSOO 1641 §112 Non-Final OA Pending Feb 22, 2022
16084392 METHODS OF TREATING OR PREVENTING GRAFT VERSUS HOST DISEASE HADDAD, MAHER M 1641 §103 Non-Final OA Pending Sep 12, 2018
16084383 METHOD OF PREVENTING GRAFT VERSUS HOST DISEASE ALDARONDO, DASIA ALI 1600 §103DP Final Rejection Pending Sep 12, 2018

Managing Millennium Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month